[Value of DNFB skin testing in patients with bladder cancer (author's transl)].
Dinitrofluorobenzene (DNFB) was used to sensitize 156 patients (124 patients with bladder cancer, 32 controls) to test their ability to be immunized with a newly encountered antigen. All control persons had a normal reaction to DNFB. 16.1% of the tumor patients reacted anerg. The reactivity of the cancer patients depended on the tumor stage. Patients with stage T 1 tumors reacted more positive than those with stage T 3 tumors. Unfortunately, these results had only a value for a group of patients and cannot be extrapolated for application to a given patient. Our results suggested that the prognosis of a cancer patient could be depend of the skin reactivity result. DNFB skin testing is a good method for the estimation of immune status in bladder cancer.
D000368:Aged; D004139:Dinitrofluorobenzene / Q000276:immunology; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009578:Nitrobenzenes; D011379:Prognosis; D012882:Skin Tests; D001749:Urinary Bladder Neoplasms / Q000276:immunology*
D009578:Nitrobenzenes; D004139:Dinitrofluorobenzene
Beitrag zur Wertigkeit der DNFB-Hauttestung beim Harnblasenkarzinom.